218 related articles for article (PubMed ID: 27813420)
1. Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies.
Koutkias VG; Lillo-Le Louët A; Jaulent MC
Expert Opin Drug Saf; 2017 Feb; 16(2):113-124. PubMed ID: 27813420
[TBL] [Abstract][Full Text] [Related]
2. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
3. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.
Fernandez S; Lenoir C; Samer C; Rollason V
Pharmacol Res Perspect; 2020 Oct; 8(5):e00647. PubMed ID: 32881416
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
5. Social Media Listening for Routine Post-Marketing Safety Surveillance.
Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
[TBL] [Abstract][Full Text] [Related]
6. Mining heterogeneous networks with topological features constructed from patient-contributed content for pharmacovigilance.
Yang CC; Yang H
Artif Intell Med; 2018 Aug; 90():42-52. PubMed ID: 30093253
[TBL] [Abstract][Full Text] [Related]
7. A Multiagent System for Integrated Detection of Pharmacovigilance Signals.
Koutkias V; Jaulent MC
J Med Syst; 2016 Feb; 40(2):37. PubMed ID: 26590975
[TBL] [Abstract][Full Text] [Related]
8. Exploiting Social Media for Active Pharmacovigilance: The PVClinical Social Media Workspace.
Kakalou C; Dimitsaki S; Dimitriadis VK; Natsiavas P
Stud Health Technol Inform; 2022 Jun; 290():739-743. PubMed ID: 35673115
[TBL] [Abstract][Full Text] [Related]
9. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
[TBL] [Abstract][Full Text] [Related]
10. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
11. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
12. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
Shin H; Lee S
BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
[TBL] [Abstract][Full Text] [Related]
13. Utilizing social media data for pharmacovigilance: A review.
Sarker A; Ginn R; Nikfarjam A; O'Connor K; Smith K; Jayaraman S; Upadhaya T; Gonzalez G
J Biomed Inform; 2015 Apr; 54():202-12. PubMed ID: 25720841
[TBL] [Abstract][Full Text] [Related]
14. Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.
Li Y; Jimeno Yepes A; Xiao C
Drug Saf; 2020 Sep; 43(9):893-903. PubMed ID: 32385840
[TBL] [Abstract][Full Text] [Related]
15. Filtering big data from social media--Building an early warning system for adverse drug reactions.
Yang M; Kiang M; Shang W
J Biomed Inform; 2015 Apr; 54():230-40. PubMed ID: 25688695
[TBL] [Abstract][Full Text] [Related]
16. Drug safety and big clinical data: Detection of drug-induced anaphylactic shock events.
Bouzillé G; Osmont MN; Triquet L; Grabar N; Rochefort-Morel C; Chazard E; Polard E; Cuggia M
J Eval Clin Pract; 2018 Jun; 24(3):536-544. PubMed ID: 29532572
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Twitter as a complementary data source for pharmacovigilance.
Lardon J; Bellet F; Aboukhamis R; Asfari H; Souvignet J; Jaulent MC; Beyens MN; Lillo-LeLouët A; Bousquet C
Expert Opin Drug Saf; 2018 Aug; 17(8):763-774. PubMed ID: 29991282
[TBL] [Abstract][Full Text] [Related]
18. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance.
Sagud M; Breznoscakova D; Celofiga A; Chihai J; Chkonia E; Ristic Ignjatovic D; Injac Stevovic L; Kopecek M; Kurvits K; Kuzo N; Lazáry J; Mazaliauskienė R; Mladina Perisa D; Novotni A; Panov G; Pikirenia U; Rădulescu FȘ; Sukiasyan SG; Taube M; Tomori S; Wilkowska A; De Las Cuevas C; Sanz EJ; de Leon J
Schizophr Res; 2024 Jun; 268():53-59. PubMed ID: 37783650
[TBL] [Abstract][Full Text] [Related]
19. A Knowledge-Based Platform for Assessing Potential Adverse Drug Reactions at the Point of Care: User Requirements and Design.
Natsiavas P; Jaulent MC; Koutkias V
Stud Health Technol Inform; 2019 Aug; 264():1007-1011. PubMed ID: 31438076
[TBL] [Abstract][Full Text] [Related]
20. A research framework for pharmacovigilance in health social media: Identification and evaluation of patient adverse drug event reports.
Liu X; Chen H
J Biomed Inform; 2015 Dec; 58():268-279. PubMed ID: 26518315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
